Tysabri News
Most Popular Tysabri Story
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the... Read more...
Latest Headlines
- April 22, 2009
- March 26, 2009
- February 6, 2009
- August 1, 2008
- January 29, 2008
- January 10, 2008
- December 13, 2007
- November 14, 2007
- November 8, 2007
- October 15, 2007
- October 12, 2007
- August 22, 2007
- August 1, 2007
- July 23, 2007
- December 18, 2006
- October 31, 2006
- October 23, 2006
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
